At Novo Nordisk we receive many different requests for information to be used in the benchmarks etc. Instead of responding to each request or questionnaire on an individual basis, we have decided to make most of this information available online to ensure it serves a wider audience. This information-upgrade of will take place during the first half of 2019.

We will continue responding to two benchmarks, as they have been assessed to be of particular importance to us. One is the Access to Medicine Index and the other is CDP.


Access to Medicine Index

About the Index

Every other year, Novo Nordisk takes part in the extensive Access to Medicine Index (ATMI) ranking. Since 2008, the Access to Medicine Index has ranked pharmaceutical companies’ efforts to improve access to medicine in developing countries. The aim of the Index is to acknowledge and share best practices within the pharmaceutical industry. 

In 2018, Novo Nordisk was ranked tenth in the index; in 2016 we were ranked tenth; in 2014 we were ranked second; and in 2012 we were ranked sixth.

See the ATMI report card for Novo Nordisk 2018

See the 2018 Access to Medicine Index Overall Ranking


CDP (Carbon Disclosure Project)

In 2018, we were awarded the performance score ‘A’ on the CDP Climate A list - one of only three pharma companies globally. This is the 16th time we submit information to the CDP report.

About the index

CDP is a not-for-profit organisation that runs the global disclosure system for investors, companies, cities, states and regions to manage their environmental impacts.

See the detailed CDP score here

Read Novo Nordisk’s contribution to CDP’s ‘Stories of Change’ report about how companies are taking action on climate change here


CDP Climate A list